Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Reaching deep and being resourceful were the in-demand attributes that medtech industry leaders brought to bear when the COVID-19 pandemic stretched health care providers almost to breaking point.
Royal Philips anticipated a degree of negative sentiment from health system managers about the outlook for innovation and progress in health care delivery when it polled the provider C-suite for its 2021 Future Health Index report. It was surprised by the actual outcome.
In conjunction with In Vivo’s Rising Leaders series, a panel of senior executives representing a wide spectrum of the life sciences industry – from large biopharmaceuticals to small biotech and cancer diagnostics – was convened to discuss what it takes to successfully lead during times of uncertainty and upheaval. Insights on communication strategies, navigating team integrations, supporting diversity and inclusion, and getting the most from multi-generational employees rested on a common theme: valuing people and anticipating workforce needs.
Job candidates have the upper hand right now, but recruiters, investors and employers say there are ways to attract, elevate and retain qualified candidates beyond just paying higher salaries.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The EU Medical Device Regulation came into effect on 26 May, but the hard work is still all to do to ensure patient care is not disrupted, innovation flow is maintained and Europe remains an attractive place to do business, says MedTech Europe’s Serge Bernasconi.
Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem.
Smaller physicians’ offices often lack the resources and expertise to perform ultrasound exams to the highest standards. This realization incentivized ultrasound technician Denise Barbato to found her own company to reimagine the service offered.
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who is in the spotlight this year.
Sarah Howell, one of In Vivo’s 2021 Rising Leaders, was appointed CEO of Arecor in 2015 and has led the company’s transformation into a successful clinical-stage biotechnology company. In an exclusive interview, Howell described Arecor as focused on “affordable innovation,” particularly in disease areas with large and growing patient populations, such as diabetes.
In Vivo’s 2021 Rising Leader Alvine Tremoulet favored backroads over the corporate highway en route to her current position as global diversity, equity and inclusion lead at Pfizer. Tremoulet’s background in communications, and a strong network of female leaders, helped her to successfully influence internal and external stakeholders on issues still considered taboo in many parts of the world.
30 Rising Leaders who are making waves and challenging traditional structures across the biopharma and medtech sectors. In Vivo's 2021 list also includes industry stars that have raised their game in response to the COVID-19 pandemic.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.